Clinical Trial

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Protocol Amendment History 33 amendments
This ClinicalTrials.gov record has been amended 33 times since 2025-08-29; most recent amendment 2026-06-15.
Status change: Not Yet Recruiting → Recruiting 2025-10-17
Trial Details
NCT Number NCT07160608
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Enrollment 75 participants
Start Date 2025-11-26
Primary Completion 2027-10-11 (estimated)
Study Completion 2028-02-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-16